Impact of<i> PIK3CA</i> and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
- Authors
- Kim, Dong Hyun; Lim, Seung Taek; Kim, Hye Ryun; Kang, Eun Joo; Ahn, Hee Kyung; Lee, Yun- Gyoo; Sun, Der Sheng; Kwon, Jung Hye; Lee, Sang-Cheol; Lee, Hyun Woo; Kim, Min Kyoung; Keam, Bhumsuk; Park, Keon-Uk; Shin, Seong-Hoon; Yun, Hwan Jung
- Issue Date
- Apr-2024
- Publisher
- ELSEVIER
- Keywords
- Head and neck squamous cell carcinoma; Durvalumab; PI3KCA; Cell cycle pathway; Neutrophil-lymphocyte ratio; Platelet-lymphocyte ratio
- Citation
- ORAL ONCOLOGY, v.151
- Journal Title
- ORAL ONCOLOGY
- Volume
- 151
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91213
- DOI
- 10.1016/j.oraloncology.2024.106739
- ISSN
- 1368-8375
1879-0593
- Abstract
- Objectives: This study aimed to investigate whether genetic alterations in PI3KCA and the cell cycle pathways influence the efficacy of durvalumab, an immune checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) who had previously failed platinum-based treatment. Materials and methods: We obtained data from a phase II umbrella trial of patients with HNSCC who failed platinum-based treatment (TRIUMPH, NCT03292250). Patients receiving durvalumab treatment comprised those with PIK3CA alterations (Group A), those with cell cycle pathway alterations such as CDKN2A (Group B), and those with no druggable genetic alterations (Group C). We analyzed the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in each group and evaluated the potential predictive factors for durvalumab. Results: We analyzed the data of 87 patients: 18, 12, and 57 in groups A, B, and C, respectively. The ORRs were 27.8 %, 8.3 %, and 15.8 % in Groups A, B, and C, respectively (P = 0.329), and the median PFS for each group was 2.3, 1.6, and 1.7 months, respectively, with no significant differences between the groups (P = 0.24). Notably, patients with lower neutrophil-lymphocyte ratio (NLR) (<= 5.8) had longer PFS (median, 2.8 vs 1.6 months, P < 0.001), while those with lower platelet-lymphocyte ratio (PLR) (<= 491.2) exhibited longer PFS (median, 1.8 vs 1.2 months, P < 0.001). Conclusion: Durvalumab's efficacy was similar, irrespective of the presence of PIK3CA or cell cycle pathway genetic alterations in patients with platinum-resistant HNSCC. The NLR and PLR may be promising predictive biomarkers.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91213)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.